大流行
药物重新定位
医学
冠状病毒
重新调整用途
临床试验
2019年冠状病毒病(COVID-19)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
爆发
重症监护医学
药品
药物发现
埃博拉病毒
抗病毒药物
药物开发
药理学
病毒学
疾病
传染病(医学专业)
生物信息学
内科学
生物
生态学
作者
Bharat Goel,Nivedita Bhardwaj,Nancy Tripathi,Shreyans K. Jain
出处
期刊:Mini-reviews in Medicinal Chemistry
[Bentham Science]
日期:2020-12-28
卷期号:21
被引量:4
标识
DOI:10.2174/1389557521666201228145755
摘要
: Recently, a sudden outbreak of novel coronavirus disease (COVID-19) was caused by a zoonotic virus known as severe acute respiratory syndrome coronavirus (SARS-CoV-2). It has caused pandemic situations around the globe and affecting the lives of millions of people. So far, no drug has been approved for the treatment of SARS-CoV-2 infected patients. As of now, more than 1000 clinical trials are going on for repurposing of FDA approved drugs and for evaluating the safety & efficiency of experimental antiviral molecules to combat COVID-19. Since the development of new drugs may require months to years to reach the market, this review focusses on the potentials of existing small molecule FDA approved drugs and the molecules already in the clinical pipeline against viral infections like HIV, hepatitis B, Ebola virus, and other viruses of coronavirus family (SARS-CoV and MERS-CoV). The review also discusses the natural products and traditional medicines in clinical studies against COVID-19. Currently, 1978 studies are active, 143 completed and 4 posted results (as on June 13, 2020) on clinicaltrials.gov.
科研通智能强力驱动
Strongly Powered by AbleSci AI